Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The injectable anticoagulants include low molecular weight heparin (LMWH) agents (dalteparin [Fragmin®], enoxaparin [Lovenox®]) and factor Xa inhibitors (fondaparinux [Arixtra®]).
Scope of the Report:
In the last several years, global market of injectable anticoagulants developed slowly. In 2016, global revenue of injectable anticoagulants is nearly 5300 M USD. And the global growth rate is slow.
The classification of injectable anticoagulants includes LMWH, DTI and other, and the proportion of LMWH in 2016 is about 55%, and the proportion is in decreasing trend from 2012 to 2016.
Injectable anticoagulants are widely used for VTE, ACS/MI, AF and other field. The most proportion of injectable anticoagulants used to treat AF, and the revenue in 2016 is 3400 M USD.
The worldwide market for Injectable Anticoagulants is expected to grow at a CAGR of roughly 2.7% over the next five years, will reach 6440 million US$ in 2024, from 5490 million US$ in 2019, according to a new WMR study.
This report focuses on the Injectable Anticoagulants in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Sanofi
Genentech (Roche)
Boehringer Ingelheim
Pfizer
The Medicines Company
Aspen
Otsuka
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Low-molecular-weight Heparin (LMWH)
Direct Thrombin Inhibitor (DTI)
Other
Market Segment by Applications, can be divided into
VTE
ACS/MI
AF
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Injectable Anticoagulants product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Injectable Anticoagulants, with price, sales, revenue and global market share of Injectable Anticoagulants in 2017 and 2018.
Chapter 3, the Injectable Anticoagulants competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Injectable Anticoagulants breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Injectable Anticoagulants market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Injectable Anticoagulants sales channel, distributors, customers, research findings and conclusion, appendix and data source.